Legal & General Group Plc acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 711,233 shares of the company’s stock, valued at approximately $17,503,000. Legal & General Group Plc owned about 0.14% of Elanco Animal Health at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of ELAN. BlackRock Inc. purchased a new position in Elanco Animal Health in the 2nd quarter worth approximately $1,202,198,000. T. Rowe Price Investment Management Inc. raised its holdings in Elanco Animal Health by 11.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Elanco Animal Health by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock worth $567,622,000 after acquiring an additional 373,869 shares during the last quarter. UBS Group AG grew its holdings in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Elanco Animal Health by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock valued at $213,343,000 after acquiring an additional 640,098 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.
Insider Activity at Elanco Animal Health
In other Elanco Animal Health news, CFO Robert M. Vanhimbergen purchased 4,200 shares of the stock in a transaction dated Friday, August 7th. The shares were purchased at an average cost of $23.08 per share, with a total value of $96,936.00. Following the completion of the acquisition, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This trade represents a 3.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Paul Herendeen acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the transaction, the director directly owned 111,687 shares of the company’s stock, valued at $2,644,748.16. The trade was a 9.83% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 63,198 shares of company stock valued at $1,473,109 over the last ninety days. Corporate insiders own 1.14% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on ELAN
Elanco Animal Health Trading Up 0.2%
NYSE ELAN opened at $24.16 on Monday. The stock has a market cap of $12.07 billion, a P/E ratio of -58.93, a P/E/G ratio of 1.44 and a beta of 1.67. The stock’s fifty day moving average price is $24.62 and its 200-day moving average price is $24.00. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. Elanco Animal Health’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.
Elanco Animal Health Profile
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.
Read More
- Five stocks we like better than Elanco Animal Health
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
